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RESEARCH AWARDS RENEWED
FOR TWO NEW INVESTIGATORS
Research awards have been re-
newed for two new investigators at
the University of Michigan and at
M.D. Anderson Cancer Center.
ASBMT/ESP Pharma. The recipient
of a new investigator award from
ASBMT and ESP Pharma has submitted
a mid-project progress report on his
research on the role of antigen-present-
ing cells in mediating graft-versus-leuke-
mia (GvL) effect after experimental allo-
geneic bone marrow transplantation.
Pavan Reddy, MD, an assistant pro-
fessor in the adult blood and marrow
transplant program at the University of
Michigan Medical School, has achieved
the first goal of his research: to deter-
mine the role of host antigen-present-
ing cells (APCs) and pro-inflammatory
cytokines in inducing a GvL response
after bone marrow transplantation. In
tumor models of GvL mediated by
CD8 or CD4 donor T-cells, the de-
velopment of a GvL response required
the presence of functional APCs to
present tumor antigens and/or alloan-
tigens. Without APCs, direct presenta-
tion of antigen by tumors elicited no
acute GvL effect, even though co-stim-
ulatory molecules were expressed.
Preliminary experiments also have
been performed examining the contri-
butions of tumor antigen expression
and pro-inflammatory cytokines to GvL
responses. Confirmatory studies are un-
der way, and chimeric mice are being
generated to examine the role of cyto-
kines in mediating the GvL.
Based on his progress to date, the
$25,000-per-year ASBMT/ESP Pharma
New Investigator Award has been re-
newed for a second year for Dr. Red-
dy’s research.
ESP Pharma, Inc, earlier this year
became a wholly owned subsidiary of
Protein Design Labs, Inc.
ASBMT/Astellas. A new investigator
award from ASBMT and Astellas
Pharma US, Inc., (formerly Fujisawa
Healthcare) has submitted a mid-
project progress report on his research
concerning ways to elicit donor cyto-
toxic T-lymphocytes (CTLs) specifically tar-
geted against a previously identified leu-
kemia-associated antigen, termed PR1.
Sijie Lu, PhD, is an instructor at the
M. D. Anderson Cancer Center at the
University of Texas, Houston, and a
member of the cancer center’s De-
partment of Blood and Marrow Trans-
plantation, Section of Transplant
Immunology. His group at M.D.
Anderson proposed to develop mi-
crobeads coated with synthetic PR1-
HLA protein complexes to select and
purify peptide-specific cytotoxic T-lym-
phocytes (CTLs) from donor lympho-
cytes. Initial results showed no signif-
icant difference in the number of PR1-
specific CTLs between donors positive
vs. negative for HLA-A2. Because of
the low frequency of PR1-CTLs in
healthy donors, the researchers shifted
their focus to eliciting PR1-CTLs, then
isolating them from expanded cultures.
Toward that end, Dr. Lu and col-
leagues have developed a technique of
purifying in vitro folded PR1/HLA-A2
complex and are working on methods
of purifying human 4-1BB ligand from
host cell lines. By coupling HLA-A2/PR1
complex, CD80-Fc, and soluble 4-1BBL
to microbeads, they have succeeded in
creating an initial version of PR1-specific
artificial antigen-presenting cells. The
next step will be to test the ability of
these artificial cells to elicit PR1-CTLs
from HLA-A2-positive donors, com-
pared with autologous dendritic cells.
Based on his progress to date, the
$25,000-per-year award for Dr. Lu’s
research has been renewed for a sec-
ond year.
NEW INVESTIGATORS ELIGIBLE
FOR $5,000 EDITORIAL AWARDS
Each year ASBMT presents two ed-
itorial awards to new investigators
published in Biology of Blood and
Marrow Transplantation.
● George Santos Award for best
clinical research article
● Ernest McCulloch & James Till
Award for best basic science article
Both awards are accompanied by a
$5,000 prize that is presented at the
BMT TandemMeetings. The two awards
are supported by educational grants
from StemCell Technologies, Inc. and
StemSoft Software Inc., Vancouver.
Recipients must be not more than
five years past a graduate or post-doc-
toral program or a clinical research fel-
lowship, or currently active in a training
program as a clinical resident or fellow,
post-doctoral fellow, medical student,
graduate student or undergraduate
student. The winning articles must
have been published in the 2005 vol-
ume (Vol. 11) of the journal.
Many authors choose Biology of
Blood and Marrow Transplantation
for submitting basic and clinical re-
search articles because:
● The readership is highly focused in
the field of hematopoietic progen-
itor stem cell transplantation.
● The turnaround time from article ac-
ceptance to publication averages
40 days for a “rapid publication”
and 75 days for a regular article.
● There are no author page charges.
● The journal has an ISI Impact Fac-
tor of 3.278, ranking it among the
top transplant journals.
The judging committee for the edito-
rial awards is the BBMT Editorial Board
and ASBMT Publications Committee.
RECORD PRE-REGISTRATION AND
ABSTRACTS FOR MEETING IN HAWAII
Early registration for the BMT Tan-
dem Meetings in Honolulu are run-
ning 46 percent ahead of this year’s
record attendance in Keystone, and
accepted abstracts are 56 percent
above this year’s record number.
The 2006 meetings will be held
Feb. 16-20 at the Hawaii Convention
Center. Visit the ASBMT Web site
www.asbmt.org for online registra-
tion and housing reservations.
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